Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Advanced Breast Cancer
Interventions: DRUG: Abemaciclib|DRUG: Hydroxychloroquine 200 mg|DRUG: Faslodex|DRUG: Anastrazole|DRUG: Letrozole|DRUG: Hydroxychloroquine 400 mg|DRUG: Hydroxychloroquine 600 mg
Sponsor: Medical College of Wisconsin